NCT03160118View on ClinicalTrials.gov

Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

May 17, 2017

Study Completion Date

June 28, 2017

Conditions
Prevention of Influenza
Interventions
DRUG

Seasonal,quadrivalent,influenza vaccine

1 dose to be administered on Day 0, the first visit

Trial Locations (1)

9000

University Hospital - Center for Vaccinology, Ghent

All Listed Sponsors
collaborator

CEVAC Core Lab, University Ghent

UNKNOWN

collaborator

Max Planck Institute for Infection Biology (MPIIB), Berlin, Germany

UNKNOWN

collaborator

deCODE genetics, Iceland

UNKNOWN

collaborator

VisMederi srl, Sienna, Italy

UNKNOWN

lead

University Hospital, Ghent

OTHER

NCT03160118 - Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults | Biotech Hunter | Biotech Hunter